Premium
Scl 70 antibody—a specific marker of systemic sclerosis
Author(s) -
JARZABEKCHORZELSKA MARIA,
BLASZCZYK MARIA,
JABLONSKA STEFANIA,
CHORZELSKI T.,
KUMAR V.,
BEUTNER E.H.
Publication year - 1986
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1986.tb06233.x
Subject(s) - anti nuclear antibody , scleroderma (fungus) , antibody , crest syndrome , medicine , pathology , immunofluorescence , indirect immunofluorescence , systemic scleroderma , staining , homogeneous , autoantibody , connective tissue disease , immunology , autoimmune disease , dermatomyositis , inoculation , physics , thermodynamics
Scl 70 antibodies were tested for in 107 patients with systemic sclerosis: 68 with acrosclerosis and 39 with diffuse scleroderma. Anticentromere antibodies (ACA) and other antinuclear antibodies (ANA) were tested for by indirect immunofiuorescence on HEp‐2 cells. Positive results for Scl 70 antibodies were obtained in 77percnt; of cases of diffuse scleroderma and 44percnt; of acrosclerosis. ACA and Scl 70 antibodies were found to be mutually exclusive. If acrosclerosis cases positive for anticentromere antibodies are excluded, the percentage of acrosclerosis cases positive for Scl 70 was 63percnt;. ACA were found to be a marker of a benign, abortive subset of acrosclerosis with almost no cutaneous involvement (CREST), whereas Scl 70 did not discriminate between acrosclerosis and diffuse scleroderma. On HEp‐2 cells Scl 70 positive sera gave a characteristic, fine speckled, almost homogeneous nuclear staining pattern.